Kringle Pharma, Inc. announced that it has received ¥610 million in a round of funding led by DBJ Capital Co., Ltd. and Keio Innovation Initiative Inc. on December 5, 2016. The transaction also involved participation from The Toho Lease Co., Ltd., The Gogin Capital Co. Ltd., KSP Inc., CYBERDYNE Inc., Nippon Zenyaku Kogyo Co.,Ltd., and ReproCELL, Inc. (JASDAQ:4978).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
650 JPY | +13.24% | +19.27% | -13.56% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
195 JPY | -0.51% | -3.94% | 265M | ||
132 JPY | +1.54% | -1.49% | 75.95M | ||
1st Jan change | Capi. | |
---|---|---|
-13.56% | 27.48M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+28.31% | 12.16B | |
+24.73% | 12.17B |
- Stock Market
- Equities
- 4884 Stock
- News Kringle Pharma, Inc.
- Kringle Pharma, Inc. announced that it has received ¥610 million in funding from a group of investors